The Nerivio therapeutic wearable for treating migraine pain won the “Best New Technology Solution for Pain Management” award in the fifth annual MedTech Breakthrough Awards program that attracted more than 3,850 nominations from 17 countries.

Nerivio is made by Netanya-based Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions.

The FDA-approved device uses remote electrical neuromodulation to activate the body’s native conditioned pain modulation mechanism to treat headache and other symptoms associated with migraine. The treatment is personalized through the Nerivio app (iPhone and Android), which also includes an interactive migraine diary to track treatment sessions and symptoms.

“Migraine is the third most prevalent disorder in the world and affects approximately 1 billion people,” said James Johnson, managing director, MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“Nerivio addresses this challenging condition by encompassing the best elements of MedTech solutions, including a true digital health non-invasive treatment approach that deploys an innovative mechanism of action and an accompanying app that controls the device while enabling patients to track and manage their migraines,” he said.

Since being launched, Nerivio has treated more than 100,000 migraines in over 14,000 patients, by prescription.

“A true advancement in digital health, Nerivio is changing the traditional migraine treatment paradigm and will continue to positively impact patients, by providing pain relief and enabling people get back to life,” said Alon Ironi, CEO and cofounder of Theranica.